About Us
Neurent Medical is pioneering innovative treatments for chronic inflammatory sino-nasal diseases by targeting and safely disrupting hyperactive autonomic nerves that drive underlying inflammation. Neurent’s proprietary NEUROMARK® technology with its unique design and advanced algorithmic control enables physicians to precisely target and safely disrupt multiple underlying nerve branches to alleviate Chronic Rhinitis symptoms and improve patient quality of life. The company is headquartered in Galway, Ireland and has its US offices in Boston, MA.
Co-founder & CEO
Board Member
Brian Shields
Brian Shields is the co-founder and CEO of Neurent Medical. Brian spent almost a decade working as a management consultant much of this time spent on the design and commercial rollout of connected health clinical programmes in public and private European health systems and “around the pill” services for the pharmaceutical industry. Brian and David founded Neurent Medical, raising their first capital in 2017. Brian has a PhD in Applied Computing and an MBA.
Chief Financial Officer
Declan Daly
Declan is a Fellow of Chartered Accountants Ireland. He has a B.A. (Moderatorship) degree in Management Science & Information System Studies from Trinity College, Dublin and a Professional Diploma in Accounting from Dublin City University.
VP of Clinical, Regulatory & Quality
Karen Peterson
Karen is responsible for clinical, regulatory, and quality at Neurent Medical. Karen has significant executive leadership experience in the medical device industry in the areas of clinical, regulatory, and quality for both large and start-up companies, including ten years in the ENT space. She has a successful track record in designing and running clinical studies, obtaining positive clinical study outcomes, obtaining numerous FDA and worldwide regulatory approvals, and ensuring successful QMS audits. Karen holds a Master of Science degree in Biometry and Health Information Systems from the University of Minnesota, and a Bachelor of Science degree from the University of Wisconsin.
John Peterson
John has over 10 years of medical device industry experience in sales management, strategy and product marketing, business development, and finance. Prior to Neurent Medical, John spent 3 years at Tactile Medical leading sales and business development activities. John has extensive ENT experience including serving as VP of Business Development for Entellus Medical during their acquisition of Spirox and sale to Stryker and Director of Business Development and Portfolio Strategy for Stryker ENT including the acquisition of Arrinex. John started his career at Piper Sandler in the Med Tech investment banking and capital markets groups. John received his BA from St. Olaf College in Biology and Economics.
Chairman of the Board
Former President, Medtronic Surgical Technologies
Mark Fletcher
Board Member
Partner & CFO,
Fountain Healthcare Partners
Justin Lynch
Board Member
CEO,
WhiteSwell
Eamon Brady
Board Member
LSP
Drew Burdon
Drew Burdon, PhD, MBA, joined LSP in 2019 as an Investment Manager. Drew’s primary responsibility within LSP is to invest in private companies, and Drew has a specific focus on the health economics funds, targeting Med Tech, Digital and Diagnostic investment opportunities. Drew has been involved in many investment opportunities during his LSP career and he led the investments in One Projects (Ireland) and Neurent Medical (Ireland). Drew holds Board Director positions for both of these companies.
Prior to joining LSP, Drew had a 13-year career at Smith & Nephew, performing in a range of increasingly senior roles across a number of functional areas including R&D, commercial strategy, marketing (including product launch) and business development. Immediately prior to joining LSP, Drew was a Director of Corporate Development with Smith & Nephew, where Drew developed and transacted share and asset acquisitions, divestments and made equity investments on behalf of the company. Of particular note, Drew led the acquisitions of Rotation Medical (US) and Ceterix Orthopaedics (US). Additionally, Drew led equity investments in Trice Medical (US) and Leaf Healthcare (US) and held Board observer positions with Leaf Healthcare (US) and OrthoSpace (Israel).
General Partner
Atlantic Bridge
Gerry Maguire
Prior to joining Atlantic Bridge, he was Vice President R&D at Parthus Technologies responsible for managing a business which included divisions in Ireland, UK and USA. Gerry joined the company in 1993 and played a key role in its transition from startup to successful IPO on Nasdaq. Gerry also held senior management roles at several technology companies including Philips and Texas Instruments.
Gerry has a BA, BAI degree in Electronic Engineering from Trinity College Dublin and a Diploma in Company Direction from the Institute of Directors.
Recent News
Stay up to date with the latest news from Neurent Medical
NEUROMARK Treatment for Chronic Rhinitis Yields Significant Clinical Improvements
24th September 2024
Neurent Medical Announces Publication of Positive Long-Term
Results from Study on Chronic Rhinitis Treatment
6th June 2024
Neurent Medical Announces New CPT Code® for Chronic Rhinitis Treatment Offering Significant Symptom Improvements
13th November 2023
